Yanchun N. Meng

Shanghai, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications

Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority Trial.

Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 04, 2026

Author Correction: Enhanced CHOLESTEROL biosynthesis promotes breast cancer metastasis via modulating CCDC25 expression and neutrophil extracellular traps formation.

Author Correction: Enhanced CHOLESTEROL biosynthesis promotes breast cancer metastasis via modulating CCDC25 expression and neutrophil extracellular traps formation.

Journal: Scientific reports
Published: September 08, 2025

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD-1 Inhibitor and Niraparib in GErm-Line-mutAted Metastatic Breast Cancer.

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD-1 Inhibitor and Niraparib in GErm-Line-mutAted Metastatic Breast Cancer.

Journal: MedComm
Published: July 16, 2025

A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors.

A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors.

Journal: BMC cancer
Published: June 17, 2025

Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial.

Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial.

Journal: The oncologist
Published: May 25, 2025

Enhanced integrated therapy for breast cancer employing Honokiol-loaded mesoporous polydopamine nanoparticles in conjunction with photothermal effects and low-dose metformin.

Enhanced integrated therapy for breast cancer employing Honokiol-loaded mesoporous polydopamine nanoparticles in conjunction with photothermal effects and low-dose metformin.

Journal: APL bioengineering
Published: January 06, 2025

Retraction Note: MicroRNA-143 targets MAPK3 to regulate the proliferation and bone metastasis of human breast cancer cells.

Retraction Note: MicroRNA-143 targets MAPK3 to regulate the proliferation and bone metastasis of human breast cancer cells.

Journal: AMB Express
Published: December 28, 2024

Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial.

Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial.

Journal: PLoS medicine
Published: October 25, 2024

Reciprocal Interaction with Neutrophils Facilitates Cutaneous Accumulation of Liposomes.

Reciprocal Interaction with Neutrophils Facilitates Cutaneous Accumulation of Liposomes.

Journal: ACS nano
Published: July 01, 2024

First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors.

First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors.

Journal: NPJ precision oncology
Published: March 31, 2024

Chinese physician perception on the treatment of chemotherapy-induced anemia: online cross-section survey study.

Chinese physician perception on the treatment of chemotherapy-induced anemia: online cross-section survey study.

Journal: Chinese clinical oncology
Published: January 22, 2024

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer.

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer.

Journal: Thoracic cancer
Published: August 15, 2023
Showing 1-12 of 37

Last Updated: 09/26/2026